Best pharmacotherapy for pme treatment
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have sufficient information to provide a comprehensive answer.
Pharmacotherapy for Progressive Myoclonic Epilepsy (PME)
PME is a heterogeneous group of genetic disorders (Unverricht-Lundborg disease, Lafora body disease, MERRF, neuronal ceroid lipofuscinoses, etc.) characterized by myoclonus, generalized tonic-clonic (GTC) seizures, and progressive neurological deterioration. Treatment remains symptomatic — seizures are often resistant to medical therapy.
First-Line Agent
| Drug | Role |
|---|---|
| Valproate (valproic acid) | Drug of choice for most PME patients; broad-spectrum activity against myoclonus and GTC seizures |
| Dose range | 800–3000 mg/day |
Additional GABAergic / Broad-Spectrum Options
| Drug | Dose Range | Notes |
|---|---|---|
| Levetiracetam | 1000–3000 mg/day | Broad-spectrum; good tolerability; frequently used in combination |
| Clonazepam | 2–15 mg/day | Effective for myoclonus; sedation limits long-term use |
| Piracetam | 8–20 g/day | Anti-myoclonic; particularly effective in Unverricht-Lundborg disease |
| Primidone | 500–1000 mg/day | GABAergic; adjunctive option |
| Perampanel | — | Anecdotal evidence of particular efficacy against both myoclonus and GTC seizures in some PME patients; AMPA-receptor antagonist |
Drugs to AVOID
| Drug | Reason |
|---|---|
| Phenytoin | Worsens ataxia (especially in Unverricht-Lundborg disease) and can cause mild dementia; contraindicated |
| Carbamazepine / oxcarbazepine / lamotrigine | Can aggravate myoclonus in PME |
Combination Strategy
In many patients, combinations of drugs are necessary. A common approach:
- Valproate + levetiracetam as a backbone
- Clonazepam added for breakthrough myoclonus
- Piracetam as add-on, especially in Unverricht-Lundborg disease
- Perampanel for refractory myoclonus or GTC seizures
Disease-Specific Considerations
- MERRF (mitochondrial): Avoid valproate if there is significant mitochondrial dysfunction; levetiracetam and clonazepam preferred
- Lafora disease: Rapidly progressive; typically refractory; valproate + polytherapy standard
- Unverricht-Lundborg: Piracetam has particularly strong evidence; strictly avoid phenytoin
Sources: Bradley and Daroff's Neurology in Clinical Practice, 8e; Harrison's Principles of Internal Medicine, 22e
Phrmacotherapy for premature ejaculation
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content. Here is the full synthesis:
Pharmacotherapy for Premature Ejaculation (PE)
No drug has FDA approval specifically for PE in the US. Treatment exploits off-label drug effects or uses dapoxetine (approved in 50+ countries outside the US).
1. SSRIs / TCAs — Mainstay of Treatment
Mechanism: Block serotonin reuptake → enhanced 5-HT neurotransmission → delayed ejaculation via stimulation of postsynaptic 5-HT receptors.
Daily Dosing (Off-Label) — Greatest Ejaculatory Delay
| Drug | Dose | IELT Fold-Increase |
|---|---|---|
| Paroxetine | 10–40 mg/day | ~8.8× (strongest of all SSRIs) |
| Clomipramine (TCA) | 12.5–50 mg/day | Effective |
| Sertraline | 50–200 mg/day | Effective |
| Fluoxetine | 20–40 mg/day | Effective |
| Citalopram | 20–40 mg/day | Effective |
- Ejaculatory delay begins within 5–10 days; full effect at 2–3 weeks
- Avoid abrupt cessation — risk of SSRI withdrawal syndrome
- Caution in men with bipolar disorder (risk of hypomania/agitation)
- Paroxetine may impair sperm DNA integrity — relevant in men seeking fertility
On-Demand Dosing (3–6 hours before intercourse)
| Drug | Notes |
|---|---|
| Dapoxetine 30–60 mg | Approved drug of choice for on-demand use (50+ countries); short half-life SSRI purpose-built for PE; 1–2 hours before intercourse; 2.5–3×IELT increase |
| Clomipramine, paroxetine, sertraline, fluoxetine | Modestly effective on-demand but substantially less delay than daily dosing |
Dapoxetine is the only SSRI with a pharmacokinetic profile (rapid onset, short T½) specifically suited for on-demand dosing. Side effects: nausea, diarrhea, headache, dizziness (dose-dependent). No increased suicidal ideation in non-depressed PE men.
2. Topical Local Anesthetics
Mechanism: Reduce glans penis sensitivity → inhibit spinal ejaculatory reflex arc.
| Agent | Notes |
|---|---|
| Lidocaine/prilocaine cream or gel | Oldest pharmacologic treatment; moderately effective |
| PSD502 (Fortacin) — lidocaine/prilocaine metered spray | EU-approved; applied 5 min before intercourse; 4.6–6.3× IELT increase; penetrates only glans mucosa (not shaft skin), minimizing transfer to partner |
- Key caution: Conventional creams/gels risk transvaginal absorption → partner vaginal numbness and female anorgasmia — use a condom unless using PSD502 formulation
3. PDE5 Inhibitors (Sildenafil, Tadalafil, Vardenafil)
- Not recommended as monotherapy for PE in men with normal erectile function
- Recommended for PE with comorbid ED — alone or combined with an SSRI
- Evidence from one RCT: vardenafil on-demand → 7.5× IELT increase in potent men with lifelong PE, but overall evidence remains insufficient to recommend routinely
- A PDE5I + SSRI combination appears more effective than SSRI alone in men with both conditions
4. Tramadol (On-Demand, Off-Label)
- Centrally acting opioid analgesic with serotonergic/adrenergic activity
- Effective for ejaculatory delay on-demand
- Risks: dependence, abuse potential — limits routine use
5. α1-Adrenoceptor Antagonists
- Limited/adjunctive role; more relevant in acquired PE secondary to prostatitis/CPPS
Treatment Algorithm Summary
| PE Type | Recommended Approach |
|---|---|
| Lifelong PE (L-PE) | Daily SSRI (paroxetine preferred) or on-demand dapoxetine ± topical anesthetic ± psychosexual therapy |
| Acquired PE (A-PE) | Treat underlying cause (ED → PDE5I; hyperthyroidism; prostatitis) ± SSRI + psychosexual CBT |
| PE + comorbid ED | PDE5I alone or PDE5I + SSRI |
| Infrequent intercourse | On-demand dapoxetine or topical anesthetic preferred over daily dosing |
Key Adverse Effect Considerations
| Issue | Detail |
|---|---|
| GI bleeding | SSRIs + NSAIDs/aspirin → increased upper GI bleed risk |
| Suicidality | Risk in adolescents ≤18 and those with comorbid depression — exercise caution |
| Fertility | Paroxetine → sperm DNA fragmentation (no change in semen parameters) |
| Withdrawal | Avoid abrupt SSRI discontinuation |
Sources: Campbell-Walsh-Wein Urology, 11e; Textbook of Family Medicine, 9e
How to use fluoxetine in young adult male 80 kg weight and 30 yr old
Asking for Preferences
Finding Sources
Reading File
I have all the data needed. Here is a precise, clinically structured answer:
Fluoxetine for PE in a 30-Year-Old Male (80 kg)
Fluoxetine is used off-label for PE. Weight does not influence dosing — fluoxetine is dosed by effect, not by body weight.
Dosing
| Parameter | Details |
|---|---|
| Starting dose | 20 mg orally once daily |
| Target/maintenance dose | 20–40 mg once daily |
| Titration | Start at 20 mg; if ejaculatory delay is insufficient after 2–4 weeks, increase to 40 mg/day |
| Timing | Take at the same time each day (morning preferred to minimize insomnia) |
| On-demand alternative | 20–40 mg taken 3–6 hours before intercourse — modestly effective but substantially less delay than daily dosing |
Level of evidence: High (Campbell-Walsh-Wein Urology)
Onset of Effect
- Ejaculatory delay begins within 5–10 days of starting
- Full therapeutic effect may take 2–3 weeks
- Effect is sustained with long-term use
Practical Points for This Patient
| Consideration | Advice |
|---|---|
| Off-label use | Inform the patient — fluoxetine is not licensed specifically for PE |
| Intercourse frequency | Daily dosing is preferred for men in established relationships or frequent intercourse; on-demand dosing suits infrequent intercourse |
| Combination | Can be combined with a topical anesthetic (lidocaine/prilocaine) or PDE5 inhibitor if comorbid ED exists |
| Fertility | If this patient is trying to conceive, note that paroxetine (not fluoxetine specifically, but SSRIs as a class) has been associated with sperm DNA fragmentation — discuss if relevant |
| Alcohol | Avoid excessive alcohol — potentiates CNS effects |
Adverse Effects to Counsel On
| Effect | Notes |
|---|---|
| Nausea, diarrhea, fatigue, yawning | Common in first 1–2 weeks; usually resolve spontaneously |
| Reduced libido / delayed orgasm | Less frequent in non-depressed men than in depressed men on SSRIs |
| GI bleeding | Increased risk if combined with NSAIDs/aspirin |
| Insomnia / agitation | Rare; take in the morning |
| Do not stop abruptly | Taper when discontinuing to avoid SSRI discontinuation syndrome |
| Suicidality | Low risk in non-depressed adults >24 years; this patient at age 30 is outside the high-risk youth bracket |
Monitoring
- Review at 2–4 weeks: assess ejaculatory delay, side effects, satisfaction
- If 20 mg is insufficient → increase to 40 mg/day
- If no benefit at 40 mg after 4 weeks → consider switching to paroxetine (strongest ejaculatory delay among SSRIs, ~8.8× IELT increase) or dapoxetine (if available in your country)
Source: Campbell-Walsh-Wein Urology, 11e — Table 71.3 Drug Therapy for Premature Ejaculation
This is a shared conversation. Sign in to Orris to start your own chat.